» Authors » Mathangi Thiagarajan

Mathangi Thiagarajan

Explore the profile of Mathangi Thiagarajan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 41
Citations 5190
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu J, Cao S, Imbach K, Gritsenko M, Lih T, Kyle J, et al.
Cancer Cell . 2024 Jul; 42(7):1217-1238.e19. PMID: 38981438
Although genomic anomalies in glioblastoma (GBM) have been well studied for over a decade, its 5-year survival rate remains lower than 5%. We seek to expand the molecular landscape of...
2.
Li G, Chen L, Hsiao Y, Mannan R, Zhang Y, Luo J, et al.
Cell Rep Med . 2024 May; 5(5):101547. PMID: 38703764
Non-clear cell renal cell carcinomas (non-ccRCCs) encompass diverse malignant and benign tumors. Refinement of differential diagnosis biomarkers, markers for early prognosis of aggressive disease, and therapeutic targets to complement immunotherapy...
3.
Savage S, Wang Y, Chen L, Jewell S, Newton C, Dou Y, et al.
Clin Proteomics . 2024 Jan; 21(1):7. PMID: 38291365
Background: Omics characterization of pancreatic adenocarcinoma tissue is complicated by the highly heterogeneous and mixed populations of cells. We evaluate the feasibility and potential benefit of using a coring method...
4.
Geffen Y, Anand S, Akiyama Y, Yaron T, Song Y, Johnson J, et al.
Cell . 2023 Aug; 186(18):3945-3967.e26. PMID: 37582358
Post-translational modifications (PTMs) play key roles in regulating cell signaling and physiology in both normal and cancer cells. Advances in mass spectrometry enable high-throughput, accurate, and sensitive measurement of PTM...
5.
Li Y, Dou Y, Veiga Leprevost F, Geffen Y, Calinawan A, Aguet F, et al.
Cancer Cell . 2023 Aug; 41(8):1397-1406. PMID: 37582339
The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics datasets connecting genomic aberrations to cancer phenotypes. To facilitate pan-cancer investigations,...
6.
Dou Y, Katsnelson L, Gritsenko M, Hu Y, Reva B, Hong R, et al.
Cancer Cell . 2023 Aug; 41(9):1586-1605.e15. PMID: 37567170
We characterized a prospective endometrial carcinoma (EC) cohort containing 138 tumors and 20 enriched normal tissues using 10 different omics platforms. Targeted quantitation of two peptides can predict antigen processing...
7.
Li Y, Lih T, Dhanasekaran S, Mannan R, Chen L, Cieslik M, et al.
Cancer Cell . 2022 Dec; 41(1):139-163.e17. PMID: 36563681
Clear cell renal cell carcinomas (ccRCCs) represent ∼75% of RCC cases and account for most RCC-associated deaths. Inter- and intratumoral heterogeneity (ITH) results in varying prognosis and treatment outcomes. To...
8.
Li Q, Hu Y, Chen L, Schnaubelt M, Zhou D, Li Y, et al.
Clin Proteomics . 2022 Oct; 19(1):36. PMID: 36266629
Background: The identification of differentially expressed tumor-associated proteins and genomic alterations driving neoplasia is critical in the development of clinical assays to detect cancers and forms the foundation for understanding...
9.
Whiteaker J, Lundeen R, Zhao L, Schoenherr R, Burian A, Huang D, et al.
Front Immunol . 2021 Dec; 12:765898. PMID: 34858420
Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon,...
10.
Cao L, Huang C, Zhou D, Hu Y, Lih T, Savage S, et al.
Cell . 2021 Sep; 184(19):5031-5052.e26. PMID: 34534465
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient survival. Toward understanding the underlying molecular alterations that drive PDAC oncogenesis, we conducted comprehensive proteogenomic analysis of 140...